Compare AbCellera Biologics Inc (ABCL) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Nomura Holdings Inc — how do they compare? AbCellera Biologics Inc trades at $10.29 (market cap $2.99B), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 9.5× AbCellera Biologics Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NMR | |
|---|---|---|
Market Cap | $2.99B | $28.46B |
Sector | Health | Financials |
52-Week High | $9.76 | $10.04 |
52-Week Low | $2.78 | $6.73 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
Nomura Holdings (NMR) trades at $9.905, up 0.87% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.59, net income margin of 20.4%, and robust revenue growth to $1.66 trillion in 2025. Recent Q2 2026 earnings beat expectations, and news highlights momentum in wholesale and wealth management divisions.
Outlook remains positive due to earnings strength and undervaluation, but risks include volatile cash flows and rising debt-to-asset ratio. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
